Revenue growth was bolstered by a 9% organic increase, with Sample Management Solutions reaching $88 million and Multiomics contributing $73 million. While these figures represent progress, the company continues to manage the costs associated with quality remediation and rework activities in its Automated Stores division, which weighed on gross margins.
President and CEO John Marotta noted that while the results serve as an encouraging step, the company remains in the midst of a multi-year turnaround. The firm finalized the divestiture of its B Medical Systems business on July 1, 2026, marking a significant step in its strategic realignment. Looking ahead, Azenta adjusted its full-year revenue outlook to a range of $613 million to $618 million and anticipates improved free cash flow performance of 10% to 15% compared to the previous year.
Comments (0)
No comments yet. Be the first!